Back on March 27, 2014, I recommended that Money Morning Members pick up what I felt was the very best play in the burgeoning cannabis biotech industry.
Today, the shares have done even better than I imagined, which is why I wanted to touch base with you again.
Right now, we're going to see how it's performed, but, even better, how to maximize the "free trade" it's about to give us.
And if you missed this stock last year - no worries. We'll start you now as it continues its run - a run that took off while "popular" medical marijuana stocks cratered.Here's how we'll do it...